{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:08:27Z","timestamp":1792897707007,"version":"4.5.0"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Glioblastoma (GBM) heterogeneity, aggressiveness and infiltrative growth drastically limit success of current standard of care drugs and efficacy of various new therapeutic approaches. There is a need for new therapies and models reflecting the complex biology of these tumors to analyze the molecular mechanisms of tumor formation and resistance, as well as to identify new therapeutic targets. We established and screened a panel of 26 patient-derived subcutaneous (s.c.) xenograft (PDX) GBM models on immunodeficient mice, of which 15 were also established as orthotopic models. Sensitivity toward a drug panel, selected for their different modes of action, was determined. Best treatment responses were observed for standard of care temozolomide, irinotecan and bevacizumab. Matching orthotopic models frequently show reduced sensitivity, as the blood-brain barrier limits crossing of the drugs to the GBM. Molecular characterization of 23 PDX identified all of them as IDH-wt (R132) with frequent mutations in EGFR, TP53, FAT1, and within the PI3K\/Akt\/mTOR pathway. Their expression profiles resemble proposed molecular GBM subtypes mesenchymal, proneural and classical, with pronounced clustering for gene sets related to angiogenesis and MAPK signaling. Subsequent gene set enrichment analysis identified hallmark gene sets of hypoxia and mTORC1 signaling as enriched in temozolomide resistant PDX. In models sensitive for mTOR inhibitor everolimus, hypoxia-related gene sets reactive oxygen species pathway and angiogenesis were enriched. Our results highlight how our platform of s.c. GBM PDX can reflect the complex, heterogeneous biology of GBM. Combined with transcriptome analyses, it is a valuable tool in identification of molecular signatures correlating with monitored responses. Available matching orthotopic PDX models can be used to assess the impact of the tumor microenvironment and blood-brain barrier on efficacy. Our GBM PDX panel therefore represents a valuable platform for screening regarding molecular markers and pharmacologically active drugs, as well as optimizing delivery of active drugs to the tumor.<\/jats:p>","DOI":"10.3389\/fonc.2023.1129627","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T01:16:12Z","timestamp":1681175772000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures"],"prefix":"10.3389","volume":"13","author":[{"given":"Joshua","family":"Alcaniz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Dahlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Orthmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Haybaeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Krassnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Skofler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Kratzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne A.","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"J\u00f6dicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Linnebacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iduna","family":"Fichtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Walther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0278-6","article-title":"Erratum: The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 world health organization classification of tumors of the central nervous system: A summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy002","article-title":"Females have the survival advantage in glioblastoma","volume":"20","author":"Ostrom","year":"2018","journal-title":"Neuro Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s40478-019-0745-z","article-title":"Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients","volume":"7","author":"Radke","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2737","article-title":"MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: The DIRECTOR trial","volume":"21","author":"Weller","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B7","unstructured":""},{"key":"B8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/nejmoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"New Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy106","article-title":"Bevacizumab may improve quality of life, but not overall survival in glioblastoma: An epidemiological study","volume":"29","author":"Gramatzki","year":"2018","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-12-3002","article-title":"The definition of primary and secondary glioblastoma","volume":"19","author":"Ohgaki","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"McLendon","year":"2008","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/J.CCELL.2017.06.003","article-title":"Tumor evolution of glioma intrinsic gene expression subtype associates with immunological changes in the microenvironment","volume":"32","author":"Wang","year":"2017","journal-title":"Cancer Cell"},{"key":"B13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/J.CCR.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"B14","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3390\/cancers12040937","article-title":"Glioblastoma: Pathogenesis and current status of chemotherapy and other novel treatments","volume":"12","author":"Rajaratnam","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2336","article-title":"New hints towards a precision medicine strategy for IDH wild-type glioblastoma","volume":"31","author":"White","year":"2020","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-017-0670-3","article-title":"Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: Current preclinical and clinical development","volume":"16","author":"Zhao","year":"2017","journal-title":"Mol Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdab133","article-title":"Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter","volume":"3","author":"Qin","year":"2021","journal-title":"Neurooncol Adv"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/S00432-018-2600-1","article-title":"Treatment with 5-azacitidine delay growth of glioblastoma xenografts: A potential new treatment approach for glioblastomas","volume":"144","author":"Kratzsch","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0909\/74378\/AM\/GENOMIC-AND-PHENOTYPIC-CHARACTERIZATION-OF-A-BROAD","article-title":"Genomic and phenotypic characterization of a broad panel of patient-derived xenografts reflects the diversity of glioblastoma","volume":"26","author":"Vaubel","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1015","article-title":"Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2-amplified and TP53 wild-type glioblastomas","volume":"22","author":"Verreault","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/NM.3954","article-title":"High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response","volume":"21","author":"Gao","year":"2015","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"698","DOI":"10.5414\/CPXCES15EA09","article-title":"Animal models for personalized treatment options","volume":"55","author":"Fichtner","year":"2017","journal-title":"Int J Clin Pharmacol Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/S12967-017-1128-5","article-title":"Optimized creation of glioblastoma patient derived xenografts for use in preclinical studies","volume":"15","author":"William","year":"2017","journal-title":"J Transl Med"},{"key":"B25","unstructured":"AndrewS\n          FastQC: A quality control tool for high throughput sequence data (2018)2018"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/BIOINFORMATICS\/BTS236","article-title":"Xenome\u2013a tool for classifying reads from xenograft samples","volume":"28","author":"Conway","year":"2012","journal-title":"Bioinformatics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/BIOINFORMATICS\/BTS635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/BIOINFORMATICS\/BTV566","article-title":"Qualimap 2: Advanced multi-sample quality control for high-throughput sequencing data","volume":"32","author":"Okonechnikov","year":"2016","journal-title":"Bioinformatics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/NMETH.2251","article-title":"Streaming fragment assignment for real-time analysis of sequencing experiments","volume":"10","author":"Roberts","year":"2013","journal-title":"Nat Methods"},{"key":"B30","unstructured":"Genome analysis toolkit variant discovery in high-throughput sequencing data"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13059-016-0974-4\/TABLES\/8","article-title":"The ensembl variant effect predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.19.00132","article-title":"Integrated informatics analysis of cancer-related variants","volume":"4","author":"Pagel","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"key":"B33","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/J.CELL.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01547-8","article-title":"RNAseqCNV: analysis of large-scale copy number variations from RNA-seq data","volume":"36","author":"Ba\u0159inka","year":"2022","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41467-019-13779-x","article-title":"CaSpER identifies and visualizes CNV events by integrative analysis of single-cell or bulk RNA-sequencing data","volume":"11","author":"Serin Harmanci","year":"2020","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12859-018-2246-7\/TABLES\/2","article-title":"Gene length corrected trimmed mean of m-values (GeTMM) processing of RNA-seq data performs similarly in intersample analyses while improving intrasample comparisons","volume":"19","author":"Smid","year":"2018","journal-title":"BMC Bioinf"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/PNAS.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/JNCI\/DJV369","article-title":"Delineation of MGMT hypermethylation as a biomarker for veliparib-mediated temozolomide-sensitizing therapy of glioblastoma","volume":"108","author":"Gupta","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms14262","article-title":"Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors","volume":"8","author":"Sch\u00fctte","year":"2017","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2022.889789","article-title":"A molecularly characterized preclinical platform of subcutaneous renal cell carcinoma (RCC) patient-derived xenograft models to evaluate novel treatment strategies","volume":"12","author":"G\u00fcrgen","year":"2022","journal-title":"Front Oncol"},{"key":"B41","unstructured":"Tumor-stromal cell turnover in PDX mice"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELREP.2012.12.013","article-title":"Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ","volume":"3","author":"Joo","year":"2013","journal-title":"Cell Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/B978-012088410-0\/50040-8","article-title":"Clinical pharmacology of brain tumor chemotherapy","author":"Newton","year":"2006","journal-title":"Handb Brain Tumor Chemotherapy"},{"key":"B44","article-title":"Efficacy of temozolomide treatment in patients with high-grade glioma","volume":"29","author":"Oshiro","year":"2009","journal-title":"Anticancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0807","article-title":"Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients","volume":"10","author":"Ostermann","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/S11060-009-9937-X","article-title":"Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy","volume":"95","author":"Quinn","year":"2009","journal-title":"J Neurooncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Paleologos n, Nicholas MK, Jensen r, et\u00a0al. bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/FNEUR.2019.00042\/BIBTEX","article-title":"Triple-drug therapy with bevacizumab, irinotecan, and temozolomide plus tumor treating fields for recurrent glioblastoma: A retrospective study","volume":"10","author":"Lu","year":"2019","journal-title":"Front Neurol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.4691","article-title":"Bevacizumab plus irinotecan versus temozolomide in newly diagnosed O6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: The randomized GLARIUS trial","volume":"34","author":"Herrlinger","year":"2016","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/602812","article-title":"Bevacizumab improves quality of life in patients with recurrent glioblastoma","volume":"2011","author":"Nagpal","year":"2011","journal-title":"Chemother Res Pract"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/NEUONC\/NOX209","article-title":"A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG oncology RTOG 0913","volume":"20","author":"Chinnaiyan","year":"2018","journal-title":"Neuro Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"491","DOI":"10.4161\/CC.23372","article-title":"Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures","volume":"12","author":"Carra","year":"2013","journal-title":"Cell Cycle"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3892\/IJO.2017.4082","article-title":"Salinomycin\u2019s potential to eliminate glioblastoma stem cells and treat glioblastoma multiforme (Review)","volume":"51","author":"Magrath","year":"2017","journal-title":"Int J Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2018.1507061\/SUPPL_FILE\/IDRD_A_1507061_SM1005.TIF","article-title":"Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma","volume":"25","author":"Clavreul","year":"2018","journal-title":"Drug Delivery"},{"key":"B55","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/S11060-017-2624-4","article-title":"Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02","volume":"136","author":"Nghiemphu","year":"2018","journal-title":"J Neurooncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/NOAJNL\/VDAA124","article-title":"Phase I\/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02","volume":"2","author":"Chen","year":"2020","journal-title":"Neurooncol Adv"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/JCBFM.2012.126","article-title":"Drug transport across the blood\u2013brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J Cereb Blood Flow Metab"},{"key":"B58","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/NEUONC\/NOX175","article-title":"Is the blood\u2013brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/S10637-010-9569-1","article-title":"Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters p-gp and BCRP","volume":"30","author":"de Vries","year":"2012","journal-title":"Invest New Drugs"},{"key":"B60","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1124\/JPET.110.167601","article-title":"Distribution of gefitinib to the brain is limited by p-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux","volume":"334","author":"Agarwal","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05213-y","article-title":"Brain-restricted mTOR inhibition with binary pharmacology","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2008-072","article-title":"Neuro-oNcology sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases","volume":"11","author":"Hoffmann","year":"2009","journal-title":"Neuro Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"33440","DOI":"10.18632\/ONCOTARGET.7961","article-title":"PI3K\/Akt\/mTOR signaling pathway and targeted therapy for glioblastoma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/S13277-013-0800-5","article-title":"Targeting the PI3K\/AKT\/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding","volume":"34","author":"Sami","year":"2013","journal-title":"Tumor Biol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-018-1176-7","article-title":"Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a\/Bad\/Bax axis","volume":"9","author":"Ge","year":"2018","journal-title":"Cell Death Dis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2020.611699\/FULL","article-title":"Hypoxia-induced miR-137 inhibition increased glioblastoma multiforme growth and chemoresistance through LRP6","volume":"10","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/FNMOL.2011.00051","article-title":"PI3K\/AKT\/mTOR pathway in angiogenesis","volume":"4","author":"Karar","year":"2011","journal-title":"Front Mol Neurosci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1097\/WNR.0000000000001156","article-title":"Hypoxia enhances the migration and invasion of human glioblastoma U87 cells through PI3K\/Akt\/mTOR\/HIF-1\u03b1 pathway","volume":"29","author":"Huang","year":"2018","journal-title":"Neuroreport"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-05-0234","article-title":"Akt1 activation can augment hypoxia-inducible factor-1\u03b1 expression by increasing protein translation through a mammalian target of rapamycin\u2013independent pathway","volume":"4","author":"Pore","year":"2006","journal-title":"Mol Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1073\/PNAS.1303060110\/SUPPL_FILE\/SAPP.PDF","article-title":"Hypoxia induces a phase transition within a kinase signaling network in cancer cells","volume":"110","author":"Wei","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B71","doi-asserted-by":"publisher","first-page":"83","DOI":"10.21873\/CGP.20021","article-title":"Combination of a STAT3 inhibitor and an mTOR inhibitor against a temozolomide-resistant glioblastoma cell line","volume":"14","author":"Miyata","year":"2017","journal-title":"Cancer Genomics Proteomics"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/CANCERS12082266","article-title":"mTOR inhibition leads to src-mediated EGFR internalisation and degradation in glioma cells","volume":"12","author":"Colella","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS22094899","article-title":"Targeting RTK-PI3K-mTOR axis in gliomas: An update","volume":"22","author":"Colardo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-3153\/116090\/AM\/PHASE-II-STUDY-OF-RADIOTHERAPY-AND-TEMSIROLIMUS","article-title":"Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082)","volume":"22","author":"Wick","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-13-144\/FIGURES\/5","article-title":"MTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells","volume":"13","author":"Smalley","year":"2014","journal-title":"Mol Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS20184474","article-title":"Ronellenfitsch MW. second generation mTOR inhibitors as a double-edged sword in malignant glioma treatment","volume":"20","author":"Heinzen","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3907147","article-title":"The interplay of reactive oxygen species, hypoxia, inflammation, and sirtuins in cancer initiation and progression","volume":"2016","author":"Tafani","year":"2016","journal-title":"Oxid Med Cell Longev"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/JOP.12056","article-title":"Reactive oxygen species activation of MAPK pathway results in VEGF upregulation as an undesired irradiation response","volume":"42","author":"Drigotas","year":"2013","journal-title":"J Oral Pathol Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBRC.2013.06.096","article-title":"Aberrant, ectopic expression of VEGF and VEGF receptors 1 and 2 in malignant colonic epithelial cells. implications for these cells growth via an autocrine mechanism","volume":"437","author":"Ahluwalia","year":"2013","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1129627\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T01:16:18Z","timestamp":1681175778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1129627\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":80,"alternative-id":["10.3389\/fonc.2023.1129627"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1129627","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,11]]},"article-number":"1129627"}}